Intermittent hypoxemia and OSA: implications for comorbidities.
Level 5 - mechanism / opinion, no new human data
Narrative review synthesizing mechanistic and observational literature without systematic review methodology.
PubMed 25560865 · doi:10.1378/chest.14-0500
What was done
This narrative review evaluated findings from animal models, human mechanistic investigations, and observational population studies to examine how high-frequency intermittent hypoxemia in obstructive sleep apnea (OSA) drives chronic comorbidities, as well as the therapeutic effects of CPAP.
What was found
The abstract reports no quantitative values, confidence intervals, or sample sizes. It summarizes that cyclic intermittent hypoxemia with reoxygenation induces ischemia-reperfusion injury, reactive oxygen species production, sympathetic activation with blood pressure elevation, angiogenesis, and systemic endothelial inflammation. These mechanisms are linked to cardiovascular disease, metabolic dysfunction, neurocognitive decline, and cancer progression, while CPAP reversal of OSA yields variable clinical benefits across patient subgroups.
Why it matters
The review clarifies that intermittent hypoxemia is a distinct, central driver of multiorgan end-tissue damage in OSA, differentiating its cyclical ischemia-reperfusion pathology from sustained hypoxia.
Limits
The publication is a narrative review providing no primary quantitative data or systematic search parameters. It does not resolve the confounding interactions between obesity and intermittent hypoxemia, nor does it quantify differences between short-term and long-term hypoxemic exposure.
Cited by
- supports Sleep apnea is strongly associated with increased long-term mortality risk, impaired cognitive function, mood dysregulation, reduced athletic performance and recovery, and poor metabolic health.